Full title: Golimumab dose Optimisation to Adequate Levels to Achieve Response in Colitis

Details: GOAL-ARC is a nationwide multi-centred investigator initiated randomized control trial to evaluate the use of personalized Golimumab (GLM) dose adjustment in ulcerative colitis. The primary objective is to ascertain if dose adjustment of GLM, based on GLM drug levels and FCP levels, results in higher response and remission rates than standard SmPC dosing

Specialty: Gastroenterology

Principal Investigator: Professor Laurence Egan

Study status: Follow up 

Identifier: n/a